MOUNTAIN VIEW, Calif. – April 6, 2023 — HeartFlow, Inc., the leader in revolutionizing precision heart care, today announced the close of a $215 million Series F funding round by its parent company, HeartFlow Holding, Inc. led by Bain Capital Life Sciences with participation from new investor, Janus Henderson Investors and existing investors, including Baillie Gifford, Capricorn Investment Group Hayfin Capital Management, HealthCor, Martis Capital, USVP and Wellington Management. This new funding will enable HeartFlow to meet the growing demand for its commercial products, support a robust body of growing clinical evidence and advance its comprehensive product portfolio to help physicians to diagnose coronary artery disease (CAD) and guide their treatment decisions.
The financing follows a period of remarkable growth for HeartFlow. Coronary computed tomography angiography (CCTA) and FFRCT have already been recognized by the recent ACC/AHA Chest Pain Guidelines, and HeartFlow’s FFRCT technology is covered by 100% of Medicare and over 98% of commercial payers. With the recent FDA clearance of new products, the company is the first and only company to provide non-invasive coronary artery anatomy (RoadMap analysis), physiology(HeartFlow® FFRCT), and plaque information (Plaque analysis) based on CCTA. These products enable physicians to gain more understanding of a patient’s CAD and are the most comprehensive approach to predict risk of a heart attack.1
The HeartFlow product pipeline is expected to continue to propel the company’s position as a precision diagnostics leader. HeartFlow’s additional product launches will enable the company to further support physicians in their commitment to improve cardiovascular patient outcomes.